Josh Cooper

Josh Cooper is a Principal Scientist at Inotiv, specializing in LCMS bioanalytical method development and study conduct to assess ADME properties of drug substances since August 2021. Prior experience includes a decade at MilliporeSigma, where Josh excelled in overseeing LC-MS and quality-driven analytical activities. Leadership roles at Cerilliant Corporation involved managing Quality Control and Analytical R&D functions, focusing on method development and custom analytical projects. Additionally, Josh contributed to academic research as an Adjunct Assistant Professor at The University of Texas at Austin and directed bioanalytical laboratories in various organizations, emphasizing oncology drug development. Educational background includes a PhD in Pharmaceutical Chemistry from The University of Kansas and a BS in Biochemistry from Grove City College.